{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:39Z","timestamp":1789958799159,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.leukres.2010.07.001","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T08:52:29Z","timestamp":1281775949000},"page":"1472-1475","source":"Crossref","is-referenced-by-count":54,"title":["\u201cReal-life\u201d results of front-line treatment with Imatinib in older patients (\u226565 years) with newly diagnosed chronic myelogenous leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Roberto","family":"Latagliata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Carmosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Cuia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Diverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Loglisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Vozella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.07.001_bib0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: a model for oncology","volume":"84","author":"Helhmann","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.07.001_bib0010","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.leukres.2010.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.07.001_bib0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2010.07.001_bib0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.07.001_bib0030","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.07.001_bib0035","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.001_bib0040","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.07.001_bib0045","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.001_bib0050","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.07.001_bib0055","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk. Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2010.07.001_bib0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.07.001_bib0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.leukres.2005.03.001","article-title":"Older patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment","volume":"29","author":"Latagliata","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.07.001_bib0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.07.001_bib0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/102453308X316004","article-title":"Use of imatinib mesylate in older patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients","volume":"13","author":"Sheehy","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2010.07.001_bib0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.07.001_bib0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.07.001_bib0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.ki.5002746","article-title":"The effect of losartan on haemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes","volume":"73","author":"Mohanram","year":"2008","journal-title":"Kidney Int"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610003255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610003255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T21:52:05Z","timestamp":1544305925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0145212610003255"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.07.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}